STOCK TITAN

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Reneo Pharmaceuticals to participate in Jefferies Biotech CNS/Neuro Summit.
Positive
  • None.
Negative
  • None.

IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the Jefferies Biotech CNS/Neuro Summit.

Jefferies Biotech CNS/Neuro Summit
Date: Wednesday, October 11, 2023
Location: Jefferies Conference Center, New York, NY

About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com

Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
matthew.purcell@russopartnersllc.com


FAQ

What is Reneo Pharmaceuticals participating in?

Jefferies Biotech CNS/Neuro Summit.

When is the summit taking place?

Wednesday, October 11, 2023.

Where is the summit located?

Jefferies Conference Center, New York, NY.

Reneo Pharmaceuticals, Inc.

NASDAQ:RPHM

RPHM Rankings

RPHM Latest News

RPHM Stock Data

58.49M
14.76M
3%
82.14%
8.73%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
IRVINE

About RPHM

reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. many of these diseases are associated with deficits in cellular metabolism and energy production. our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. we are currently advancing a novel molecule into several diseases. our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.